BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17870168)

  • 1. Identification of the HLA-DM/HLA-DR interface.
    Davies MN; Lamikanra A; Sansom CE; Flower DR; Moss DS; Travers PJ
    Mol Immunol; 2008 Feb; 45(4):1063-70. PubMed ID: 17870168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape.
    Zwart W; Griekspoor A; Kuijl C; Marsman M; van Rheenen J; Janssen H; Calafat J; van Ham M; Janssen L; van Lith M; Jalink K; Neefjes J
    Immunity; 2005 Feb; 22(2):221-33. PubMed ID: 15723810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
    Narayan K; Chou CL; Kim A; Hartman IZ; Dalai S; Khoruzhenko S; Sadegh-Nasseri S
    Nat Immunol; 2007 Jan; 8(1):92-100. PubMed ID: 17143275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
    Vogt AB; Kropshofer H; Hämmerling GJ
    Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
    Weber DA; Evavold BD; Jensen PE
    Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
    Monji T; McCormack AL; Yates JR; Pious D
    J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.
    Denzin LK; Hammond C; Cresswell P
    J Exp Med; 1996 Dec; 184(6):2153-65. PubMed ID: 8976171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.
    Mosyak L; Zaller DM; Wiley DC
    Immunity; 1998 Sep; 9(3):377-83. PubMed ID: 9768757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
    van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
    Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the HLA-DM interaction site on HLA-DR molecules.
    Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
    Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
    Chou CL; Sadegh-Nasseri S
    J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
    Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
    EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules.
    Marin-Esteban V; Falk K; Rötzschke O
    J Biol Chem; 2004 Dec; 279(49):50684-90. PubMed ID: 15381703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.